Ryan Haumschild, PharmD, MS, MBA

Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.

Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.

Medical experts discuss the data gathered from the ASCERTAIN trial.

Medical experts offer insights on the COMMANDS trial findings.

Medical experts discuss risk-based approaches to choosing MDS therapies.

After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.

A group of experts discuss implications for patient access in CLL.

A panel of experts discuss navigating access challenges in CLL treatment.

Experts discuss financial challenges of BTK inhibitor therapy.

A panel of experts discuss combination regimens with BTK inhibitors.

The panel concludes its discussion by providing key takeaways on the evolving RSV vaccination landscape.

Experts on RSV provide insights on improving RSV vaccination rates, highlighting ways to navigate misinformation.

The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.

A discussion on therapeutic decision-making in CLL and the role of real-world evidence.

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

An internal medicine pharmacist discusses current and potential obstacles related to administering RSV vaccines to patients from different age groups.

Experts from clinical and payer backgrounds discuss how patients eligible for the RSV vaccine can be identified.

Heidi Crayton, MD, and Maria Lopes, MD, discuss future research in multiple sclerosis that they find exciting and promising.

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and address concerns they anticipate with the potential approval of BTKis for MS patients and strategies for mitigating these concerns.

The panelists provide their final thoughts, highlighting financial considerations in PNH treatment.

Barriers to care and treatment adherence for patients diagnosed with PNH is discussed.

A panel of experts discuss optimizing therapy sequencing in CLL.

A conversation on how to empower patients and the considerations for BTK inhibitor adherence.

Mary Bridgeman, PharmD, BCPS, BCGP, discusses how providers and healthcare workers can address vaccine fatigue in patients eligible for the RSV vaccine.

As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.

Medical experts discuss the failure of evobrutinib to meet its primary endpoint in phase 3 trials, review the primary outcomes of the phase 2B study of tolebrutinib in relapsing multiple sclerosis, examine payers' perspectives on the currently available data for tolebrutinib, and briefly describe the design of the HERCULES trial.

Heidi Crayton, MD, discusses the rationale for investigating Bruton tyrosine kinase inhibitors (BTKis) as a treatment for patients with multiple sclerosis and the current stage of development for evobrutinib, tolebrutinib, and other BTKis.

Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.

Experts on RSV vaccination discuss shared decision-making practices and the importance of getting at-risk patients vaccinated.

Specialists discuss factors influencing the choices of second-generation BTK monotherapy.